In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, Diss T, Warren B, Al Adnani M, De Goeij AP, Krausz T, Flanagan AM.
Sieben NL, et al. Among authors: krausz t.
J Pathol. 2004 Mar;202(3):336-40. doi: 10.1002/path.1521.
J Pathol. 2004.
PMID: 14991899